Raymond James Financial Inc. Purchases Shares of 746,406 Hims & Hers Health, Inc. (NYSE:HIMS)

Raymond James Financial Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 746,406 shares of the company’s stock, valued at approximately $18,048,000. Raymond James Financial Inc. owned about 0.34% of Hims & Hers Health as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after buying an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd purchased a new position in shares of Hims & Hers Health in the fourth quarter worth approximately $41,104,000. Renaissance Technologies LLC raised its holdings in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Hims & Hers Health by 613.9% in the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company’s stock valued at $30,878,000 after acquiring an additional 1,098,148 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 3,236 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the sale, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. This trade represents a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Melissa Baird sold 33,337 shares of the company’s stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total transaction of $910,766.84. Following the transaction, the chief operating officer now owns 805,083 shares of the company’s stock, valued at approximately $21,994,867.56. The trade was a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 843,271 shares of company stock worth $32,021,671 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Price Performance

NYSE HIMS opened at $27.24 on Monday. The firm has a market cap of $6.05 billion, a P/E ratio of 61.91 and a beta of 1.65. The stock’s 50-day moving average is $37.26 and its two-hundred day moving average is $30.79. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on HIMS. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Needham & Company LLC upped their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Leerink Partners boosted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $38.25.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.